Holen Sie sich die Stockscreener-App
24.05
0.39%
-0.0953
Schlusskurs vom Vortag:
$24.15
Offen:
$24.05
24-Stunden-Volumen:
123
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
$102.74M
Nettoeinkommen (Verlust:
$-95.05M
KGV:
-12.79
EPS:
-1.88
Netto-Cashflow:
$-19.23M
1W Leistung:
-0.48%
1M Leistung:
-2.17%
6M Leistung:
-6.37%
1J Leistung:
-5.91%
1-Tages-Spanne:
$24.05
$24.05
1-Wochen-Bereich:
$24.11
$24.25
52-Wochen-Spanne:
$23.87
$26.09
Flexion Therapeutics, Inc. Stock (FLXN) Company Profile
Firmenname
Flexion Therapeutics, Inc.
Sektor
Branche
Telefon
781-305-7777
Adresse
10 Mall Road, Suite 301, Burlington
Compare FLXN vs VOO, IVV, SPY, VTI, QQQ
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FLXN
Flexion Therapeutics, Inc.
|
24.05 | 0 | 102.74M | -95.05M | -19.23M | -1.88 |
VOO
Vanguard S P 500 Etf
|
712.37 | 1.05T | 0 | 0 | 0 | 0.00 |
IVV
Ishares Core S P 500 Etf
|
778.45 | 893.27B | 0 | 0 | 0 | 0.00 |
SPY
Spdr S P 500 Etf Trust
|
775.04 | 818.54B | 0 | 0 | 0 | 0.00 |
VTI
Vanguard Total Stock Market Etf
|
379.73 | 699.38B | 0 | 0 | 0 | 0.00 |
QQQ
Invesco Qqq Trust Series 1
|
737.74 | 493.40B | 0 | 0 | 0 | 0.00 |
Flexion Therapeutics, Inc. Stock (FLXN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-08-20 | Eingeleitet | Goldman | Neutral |
| 2020-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2020-07-29 | Eingeleitet | Credit Suisse | Outperform |
| 2020-06-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Buy |
| 2019-12-27 | Bestätigt | The Benchmark Company | Buy |
| 2019-12-05 | Eingeleitet | Craig Hallum | Buy |
| 2019-11-25 | Eingeleitet | BTIG Research | Buy |
| 2019-05-09 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2019-01-04 | Bestätigt | Needham | Buy |
| 2019-01-04 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2018-06-28 | Eingeleitet | The Benchmark Company | Buy |
| 2017-10-09 | Bestätigt | Needham | Buy |
| 2017-08-24 | Eingeleitet | Northland Capital | Outperform |
| 2016-12-22 | Eingeleitet | Raymond James | Strong Buy |
| 2016-09-06 | Fortgesetzt | Lake Street | Buy |
| 2016-07-21 | Eingeleitet | Lake Street | Buy |
| 2016-05-03 | Fortgesetzt | Wells Fargo | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-09-09 | Bestätigt | Needham | Buy |
Alle ansehen
Flexion Therapeutics, Inc. Aktie (FLXN) Neueste Nachrichten
Top ETFs: Live Prices, Returns & Trends - TradingKey
First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds - Business Wire
FLXR And BINC: Both Diversified, Higher-Quality Bond ETFs, Both Buys - Seeking Alpha
First Trust Announces Adjournment of Special Shareholder Meeting for First Trust Active Global Quality Income ETF - Yahoo Finance
First Trust Announces Adjournment of Special Shareholder Meeting for First Trust Active Global Quality Income ETF - Yahoo Finance
FLXN | Horizon Flexible Income ETF Insider Trading - Quiver Quantitative
Emerging Sub-Segments Transforming the Viscosupplementation Market Landscape - openPR.com
Kolon’s cell-based gene therapy fails ph.3 osteoarthritis test - Fierce Biotech
Precision Trading with Blackrock Flexible Income Etf (BINC) Risk Zones - Stock Traders Daily
Joint Pain Injections Market Report Examines Industry Trends, Growth Drivers And Future Outlook - openPR.com
Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight - Business Upturn
Osteoarthritis Therapeutics Market Size & Share | Forecast Report 2035 - Research Nester
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com Australia
Tempest Therapeutics appoints two directors to board - Investing.com UK
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com India
Tempest Therapeutics (NASDAQ: TPST) CFO to depart while two independent directors join board - Stock Titan
Tempest Therapeutics appoints two directors to board - Investing.com
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com Canada
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com UK
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - The Manila Times
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - GlobeNewswire
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - Yahoo Finance Singapore
The Best Bond Funds in 2026 - Morningstar
Osteoarthritis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharma - Barchart.com
FLXN Stock Price, Quote & Chart | HORIZON FLEXIBLE INCOME ETF (NYSEARCA:FLXN) - ChartMill
Top Players and Competitive Dynamics in the Osteoarthritis Therapeutics Market - openPR.com
BINC Can Help Stabilize The Portfolio’s Future Returns (NYSEARCA:BINC) - Seeking Alpha
Knee Osteoarthritis Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Knee Osteoarthritis Clinical Trial Pipeline Appears Robust - openPR.com
Versant Side Fund III L P Net WorthInsider Trades and Bio as of Apr 23, 2026 - Benzinga
Analysis of Key Market Segments Driving the Joint Pain Injections Market - openPR.com
Flexion Therapeutics, Inc.Common Stock (NY: FLXN - The Chronicle-Journal
Akin Advises Pharmakon in $100 Million Debt Financing for Paratek Pharmaceuticals and Radius Health Combination - akingump.com
Paratek Pharmaceuticals to Combine with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform - Sixth Street
Activist hedge fund pushes Pacira BioSciences to sell itself - The Business Journals
Intra-Articular Injections Market Companies, Size & Trends 2026-2035 - Precedence Research
BINC: Actively Managed Multi-Sector Income, Built For Carry (NYSEARCA:BINC) - Seeking Alpha
Record January ETF Flows Highlight Rotation Away From Concentration - ETF Database
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates - Finviz
Meredith Marlin Appointed as SVP, Total Rewards at Regeneron - hrtoday.in
The Standing Forward Flexion Test in Manual Therapy: A Critical Review and a Functional Reinterpretation - Cureus
Osteoarthritis Therapeutics Market Size to Hit USD 26.31 billion by 2035 - Precedence Research
Biotech Companies Hire New Legal Leadership - BioXconomy
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - Business Wire
Horizon Announces Acquisition of Anfield Capital Management - Business Wire
What’s a Safe Retirement Withdrawal Rate for 2026? - Morningstar
Your retirement income journey: Why your withdrawal rate will change over time - Moneyweb
Horizon NASDAQ-100 Defined Risk ETF (QGRD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Unlock a Worry-Free Retirement With ETFs - Investopedia
Horizon Flexible Income ETF (FLXN) Stock Price, News & Analysis - Stock Titan
Finanzdaten der Flexion Therapeutics, Inc.-Aktie (FLXN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
Kapitalisierung:
|
Volumen (24h):